

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/811,542	09/811,542 03/20/2001		Maximilian Angel	51280 9058			
26474	7590	11/05/2002					
KEIL & WI	EINKAU	F	EXAMINER				
1350 CONN WASHINGT		'AVENUE, N.W. 20036		JOYNES, RO	JOYNES, ROBERT M		
٦.				ART UNIT	PAPER NUMBER		
				1615			
				DATE MAILED: 11/05/2002	8		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)						
i	_	09/811,542	ANGEL ET AL.						
	Office Action Summary	Examiner	Art Unit						
		Robert M. Joynes	1615						
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply									
THE - Exte after - If the - If NC - Failt - Any	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing end patent term adjustment. See 37 CFR 1.704(b).	16(a). In no event, however, may a rep within the statutory minimum of thirty (fill apply and will expire SIX (6) MONTH cause the application to become ABA	ly be timely filed 30) days will be considered time 15 from the mailing date of this c						
1)⊠	Responsive to communication(s) filed on 13 A	<u> </u>							
2a)□	·	s action is non-final.							
3)									
	ion of Claims								
4)⊠	Claim(s) <u>1-5,10-13,15-21 and 23-25</u> is/are per								
	4a) Of the above claim(s) <u>6-9,14 and 22</u> is/are withdrawn from consideration.								
	Claim(s) is/are allowed.								
·	6)⊠ Claim(s) <u>1-5,10-13,15-21 and 23-25</u> is/are rejected.								
	Claim(s) <u>23-25</u> is/are objected to.								
-	Claim(s) are subject to restriction and/or	election requirement.							
	ion Papers The appellication is objected to but he Everyings								
,—	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) accep		Evaminor						
10)									
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.									
If approved, corrected drawings are required in reply to this Office action.									
12) The oath or declaration is objected to by the Examiner.									
Priority (under 35 U.S.C. §§ 119 and 120								
-	Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. §	119(a)-(d) or (f).						
	☑ All b) ☐ Some * c) ☐ None of:		, , , , , ,						
·	1.⊠ Certified copies of the priority documents	s have been received.							
	2. Certified copies of the priority documents	have been received in App	olication No						
* 5	Copies of the certified copies of the prior application from the International Bur See the attached detailed Office action for a list of the attached detailed.	reau (PCT Rule 17.2(a)).		Stage					
	* See the attached detailed Office action for a list of the certified copies not received. 1) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
_ a) The translation of the foreign language pro Acknowledgment is made of a claim for domesti	visional application has bee	en received.	, 4, 5, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1,					
ر السارة Attachmen	•	o priority under 55 0.0.0. 3	3 120 GHQ/01 121.						
1) 🔯 Notic 2) 🔲 Notic	te of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Info	mmary (PTO-413) Paper No ormal Patent Application (PT						

Application/Control Namber: 09/811,542

Art Unit: 1615

DETAILED ACTION

Receipt is acknowledged of applicants' Amendment filed on August 13, 2002.

Claim Objections

Claims 23-25 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Claims 23-25 are drawn to soft capsules and depend upon Claim 13. Claim 13 is drawn to hard capsules. Therefore, Claims 23-25 do not further the limit the subject matter of Claim 13. Appropriate corrections are required.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* **v.** *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Application/Control Nober: 09/811,542

Art Unit: 1615

Claims 1-5, 12, 13, 15, 16, 18, and 23-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over GB 922457 (hereinafter '457) in view of Harreus et al. (US 3984494). '457 teaches a graft copolymer wherein vinyl esters and ester of acrylic or methacrylic acid can be produced on polyalkylene oxides (Page 1, lines 55-69; Claim 1). The monomers of the invention can be used alone or in admixture with one another (Page 2, lines 33-48). These graft copolymers are known to be formed into films with plasticizers (Page 4, lines 22-30). '457 does not expressly teach that the polymers are formed into capsules.

Harreus et al. teach a capsule comprising polyvinyl alcohol, vinyl acetate and polyethylene oxide (Col. 1, lines 38-47; Col. 2, Example 1; Col. 3, Claim 1). The polyvinyl alcohol is present in the capsule in amounts from 20% to 98% (Col. 1, lines 38-47; Col. 3, Claim 1). The vinyl acetate is present in the capsule in amounts from 1% to 50% (Col. 1, lines 38-47; Col. 3, Claim 1). The polyethylene oxide is present in the composition in amounts from 1% to 50% (Col. 1, lines 38-47; Col. 3, Claim 1). The capsule further comprises a plasticizer (Col. 1, lines 58-68). The plasticizer is glycerol, sorbitol, cane sugar or propylene glycol (Col. 1, lines 58-68).

While the reference does not teach the complete concentration range, differences in concentration will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration is critical. Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by

Art Unit: 1615

routine experimentation. *In re Aller*, 220 F.2d 454, 105 USPQ 233, 235 (CCPA 1955).

At the time the invention was made, it would have been obvious to a person of ordinary skill in the art to prepare capsules from the polymers of '457.

One of ordinary skill in the art would have been motivated to do this to prepare improved capsules that are nearly not susceptible to attacks by microorganisms and that can be sterilized easily (Harreus, Col, 2, lines 8-11).

Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Claims 10 and 11 are rejected under 35 U.S.C. 103(a) as being unpatentable over GB 922457 (hereinafter '457) in view of Harreus et al. (US 3984494) further in view of Ishii et al. (US 5965651). The teachings of '457 and Harreus are discussed above. Neither reference teaches using a crosslinking agent.

Ishii teaches the incorporation of crosslinking agents in polymer used to prepare molded articles (Col. 2, lines 25-55). Examples of the crosslinking agents include boric acid and dicarboxylic acids (Col. 5, lines 29-63).

At the time the invention was made, it would have been obvious to a person of ordinary skill in the art to incorporate a crosslinking agent in the graft copolymer of '457.

One of ordinary skill in the art would have been motivated to do this to retain the shape of the molded polymeric article (Ishii, Col. 5, lines 44-50).

Therefore, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made.

Claims 17 and 19-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over GB 922457 (hereinafter '457) in view of Harreus et al. (US 3984494) further in view of Cade et al. (WO 9827151). The teachings of '457 and Harreus are discussed above. Neither reference teaches the what the finished capsules are filled nor do they teach an additional coating on the capsule.

Cade teaches a polymer capsule comprising a water-soluble cellulose ether, a hydrocolloid and a sequestering agent (Page 9, Claim 1). The sequestering agent can be boric acid (Page 3, lines 16-20). The capsule further comprises a coloring agent (Page 4, lines 12-21). Cade et al. teach that the capsule can be coated with a suitable coating agent (Page 4, line 22 – Page 5, line 2). The coating agent can be cellulose acetate phthalate, polyvinyl acetate phthalate, methacrylic acid polymers, hypromellose phthalate, hydroxypropylmethyl cellulose phthalate or hydroxyalkyl methyl cellulose phthalate (Page 4, line 22 – Page 5, line 2). Cade further teaches that the capsules can be filled with agrochemicals, seeds, herbs, foodstuffs, dyestuff, pharmaceuticals, flavoring agents and the like (Page 5, lines 3-5).

At the time the invention was made, it would have been obvious to a person of ordinary skill in the art to include in a polymeric capsule composition a gastric resistant coating and a filling such as a pharmaceutical.

Application/Control Namber: 09/811,542

Art Unit: 1615

One of ordinary skill in the art would have been motivated to do this to prepare a capsule with various color schemes for identification of active ingredient purposes. One of ordinary skill in the art would be motivated to add a coating to the capsule to prepare capsules of differing release profiles, for example a sustained released capsule. One would be motivated to fill the capsule with various components to facilitate effect delivery of that component.

Therefore, the invention as a whole would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made.

Response to Arguments

Applicant's arguments with respect to claims 1-5,10-13,15-21 and 23-25 have been considered but are most in view of the new ground(s) of rejection.

Conclusion

Due to the new grounds for rejection, this action is deemed non-final.

Correspondence

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Robert M. Joynes whose telephone number is (703) 308-8869. The examiner can normally be reached on Monday through Friday 8:30 - 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K. Page can be reached on (703) 308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 305-3592 for regular communications and (703) 305-3592 for After Final communications.

Art Unit: 1615

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Robert M. Joynes Patent Examiner Art Unit 1615 November 4, 2002

THURMAN K. PAGE
UPSRVSOW PATENT EXAMINER
OF CHANDLOGY CENTER 1600